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by Andre F. LeRoy*
Platinum-metal oxidation catalysts are to be introduced in exhaust systems of many 1975
model-year automobiles in the U.S. to meet Clean Air Act standards. Small quantities
of finely divided catalyst have been found issuing from prototype systems; platinum and
palladium compounds may be found also.
Although platinum exhibits a remarkable resistance to oxidation and chemical attack,
it reacts chemically under some conditions producing coordination complex compounds.
Palladium reacts more readily than platinum.
Some platinum-metal complexes interact with biological systems as bacteriostatic,
bacteriocidal, viricidal, and immunosuppressive agents. Workers chronically exposed to
platinum complexes often develop asthma-like respiratory distress and skin reactions
called platinosis. Platinum complexes used alone and in combination therapy with other
drugs have recently emerged as effective agents in cancer chemotherapy. Understanding
toxic and favorable interactions of metal species with living organisms requires basic
information on quantities and chemical characteristics of complexes at trace concentra-
tions in biological materials. Some basic chemical kinetic and thermodynamic data are
presented to characterize the chemical behavior of the complex ci8-[Pt(NH3)2Cl21 used
therapeutically. A brief discussion of quantitation of platinum at nanogram levels in
biological tissue is included.
Introduction
The platinum metals comprise the rare
metals in two triads of Group VIII of the
periodic classification of elements: ruthenium
(Ru), rhodium (Rh), palladium (Pd), and
osmium (Os), iridium (Ir), and platinum
(Pt). Standards for mobile emission sources
(primarily automobiles) have been promul-
gated; manufacturers have chosen to meet
the standards by equipping automobiles with
devices using platinum-group catalysts.
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Losses of the active metals from these devices
will expose large numbers of people to a
new environmental contaminant whose bio-
logical effects may be important. Interactions
of platinum metals and their compounds with
biological systems have been reported over
the last 140 years. The discovery that plati-
num metal complexes have a potent effect
on cell division in bacteria and some animal
tumors prompted more intensive study of
their effects on cancers of many types. There
is evidence that these platinum-metal com-
plexes interact strongly with some amino
acids, peptides, proteins, nucleotides, and nu-
cleosides, specifically with deoxyribonucleic
acid (DNA).
This paper summarizes information avail-
able on behavior of platinum metals and
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duce in biological systems exposed to them.
It describes a method of quantitation of
platinum at nanogram levels in biological
samples by atomic absorption spectrometry.
Catalytic Converters
Catalytic converters containing an esti-
mated 1-3 g (approximately 0.1 oz troy),
of platinum (Pt) and palladium (Pd) metal
have been developed to oxidize unburned hy-
drocarbon (HC) and carbon monoxide (CO)
emissions in internal combustion engine
(ICE) exhaust to water (H20) and carbon
dioxide (CO.,) to meet the standards estab-
lished in the Clean Air Act (1). Antiknock
additives containing lead alkyls and organic
halide scavengers will not be used in the
fuels for converter-equipped vehicles because
they inactivate the catalysts. Sulfur in the
fuel is oxidized to sulfur dioxide (SO2) in
the engine; this SO2 is further oxidized in
the converter to the trioxide, SO3, that com-
bines with water to produce a mist of sulfuric
acid (H2SO0) in the exhaust gas stream.
Conversion equipment involving use of a
ruthenium-based catalyst is under test to
diminish oxides of nitrogen (NO,) in the
exhaust by chemical reduction to molecular
nitrogen (N2) (2).
Catalyst and Emission Characteristics
The catalysts under consideration may be
monolithic or pelletized, with an alumina
matrix to support the active metal. Detailed
procedures used to manufacture these cata-
lysts are proprietary information that is not
generally available.
Industrial vehicles such as ICE-powered
fork-lift trucks used in ships' holds, ware-
houses, and mines have been equipped with
catalytic converters for a decade or more.
Although vehicle operating conditions and
catalyst types may differ, this application
seems to offer the best available basis for
assessment of these converters in actual use.
The U.S. Environmental Protection Agency
has made tests on a Ford Motor Company
automotive engine prototype using a mono-
lithic catalyst in its exhaust system and an
Oldsmobile (General Motors Corp.) test
vehicle equipped with a pelletized catalyst.
Data available on operating parameters
(reaction rates, temperature profiles, flow
rates and configurations) in catalytic con-
verters of each type under various operating
conditions have been closely held by the
automakers and catalyst manufacturers and
have not been disclosed.
In industrial applications, platinum gauze
oxidizing catalysts are known to undergo
substantial surface rearrangements during
catalysis at temperatures far below the melt-
ing point of the metal. Dendritic growths
appear, grain sizes increase, and attrition
occurs (3). In vehicles, there may be sig-
nificant differences in the form of catalyst
emissions from the different types under
test, e.g., alumina particles are found in the
exhaust from a vehicle with a pelletized
catalyst. Catalytic noble metals in the auto-
mobile exhaust gas stream are expected to
be very finely divided and predominantly
water-insoluble.
Loss rates of platinum and palladium of
the order of micrograms of metal per mile
have been estimated from regularly serviced
test vehicles under running conditions stipu-
lated for the modified California test cycle.
Definitive data are lacking on this point.
Industry spokesmen expect recovery of the
catalytic metals to be economically feasible.
Until the recovery rate is established, we
note that the automakers have arranged sub-
stantial supply contracts. For the coming
decade, GM agreed to buy 120,000 troy oz
Pd annually and 300,000 troy oz Pt annually
from Impala Platinum Ltd. of South Africa.
(4).
In addition to their catalytic activity,
platinum metals are well known for their
resistance to chemical attack, even at ele-
vated temperature. Indeed, many applica-
tions of the group are predicated on this
inertness. It is less well known that the
platinum group metals do react to a degree
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ness), on the presence and character of im-
purities, metallurgical history, and conditions
of dissolution (5).
There may be a tendency to think the
nobility and chemical resistance of the bulk
metal extends to the finely divided form and
conclude that it is nearly unreactive and
must therefore be innocuous. According to
Beamish (5), given sufficient fineness, the
platinum metals may be expected to respond
to the corrosive action of even single mineral
acids, particularly in the presence of air.
Losses of 1-8 g of platinum per metric ton
of sulfuric acid, depending on concentration,
were reported for some of the early methods
of production of the acid in platinum-lined
vessels (6). Palladium is subject to attack
by hot concentrated mineral acids.
It is not possible to state, definitively, the
extent to which sulfates issuing from a cata-
lytic exhaust system may include those of
platinum or palladium, without accurate in-
formation on the conditions that obtain in
the system.
Platinum is subject to net weight loss
when heated strongly in air or oxygen. De-
pending on conditions, it may incur a loss of
weight due to volatility of an oxide or a gain
resulting from formation of a stable oxide
(5). This point has been treated in an exten-
sive discussion of a century's conflicting
reports of reactions under many different
conditions (7). Formation of intermetallic
alloys within the platinum group or with
associated base metals is well known; the
effect of such alloying on the resistance to
dissolution cannot be simply inferred from
the behavior of the components (5).
Biological Response to Metals and Metal
Complexes
The critical question in biological term is:
What interactions obtain in living systems
exposed to trace concentrations of these
highly active metals, whether soluble or in-
soluble, and to the interconversion products
they may form in the environment?
Microbial Viral and Fungal Interactions
Zinno and Cutolo (8) reported an iridium
chloride solution to be highly potent against
Staphylococcus aureus and the causative or-
ganisms of typhoid, cholera, and anthrax.
A 10-min exposure to a 0.O1N solution ren-
dered spores of the anthrax bacillus non-
viable.
Shulman and Dwyer (9) in an extensive
review, compared the bacteriostatic behavior
of 1,10-phenanthroline and 2,2'-bipyridine
bases, their quaternary salts, and their metal
chelates containing identical or mixed ligands
on gram-positive (Staphylococcus pyogenes,
Streptococcus pyogenes, and Clostridium
welchii), gram-negative (Escherichia coli
and Proteus vulgaris), and acid-fast (Myco-
bacterium tuberculosis H37Rv) organisms.
They found ruthenium complexes moderately
active against the gram-positive organisms
and showed some activity against the gram-
negative microorganisms. They also report
that the expected development of drug re-
sistance with Staph. pyogenes and M. tuber-
culosis did not occur with the highly active
metal chelates of ruthenium and iron. They
report further on the inhibitory and muta-
genic activity of metal chelates on a yeast,
Saccharomyces cerevisiae, and fungistatic
activity on several pathogenic fungi.
Bromfield et al. (10) found rhodium com-
plexes of the type trans-[RhL,X,Y] (where
L is substituted pyridine; X denotes Cl- or
Br-; Y may be Cl-, Br-, NO-, or CIO,-) had
high levels of antibacterial activity. Growth
of gram-positive organisms was prevented at
concentrations of 10-100ppm. Gram-negative
bacteria (except E. coli) generally required
concentrations 10- to 100-fold higher to
arrest growth. Pyridine, substituted pyri-
dines, and rhodium trichloride are themselves
ineffective in preventing bacterial growth at
1000 ppm. Thus, the complexes exhibiting the
antibacterial activity possess the specific
characteristics resulting in this inhibition.
Rosenberg et al. (11) reported cultures of
E. coli B were killed at part-per-million
levels of [PtCI6] 2- and complexes of rhodium
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the platinum complex resulted in [PtCl4A2]
(where A is a monodentate ligand, such as
an amine) which interferes with the process
of cell division and results in filamentous
growth.
Systemic Administration of Transition
Metal Compounds in Mice
Collier and Kraus (12) treated tumorous
mice with some 64 transition metal chlorides,
including those of three platinum metals.
They reported a slight activity on mouse
sarcoma by two ruthenium compounds and
no significant effect by the rhodium and
osmium compounds they used. Taylor and
Carmichael (13) studied effects of some 37
transition metal chlorides and nitrates on
mouse mammary adenocarcinoma and trans-
plantable sarcoma in DBA mice. The results
were favorable with rhodium and iridium
chlorides, but apparently these agents were
not studied further. Rosenberg (14) also
found that the square-planar complexes cis-
[PtCl2(NH3)2], [Pt(en)CI], and the octa-
hedral complexes cis-[Pt(NH3)2C14] and
[Pt(en)Cl,] (where en denotes ethylenedi-
amine) arrest some tumor growths, e.g.,
sarcoma-180 in mice, and are effective also
against murine leukemia (L-1210) cells. Gale
et al. (15) found that photochemical reaction
products of ammonium hexachloroiridate
(IV), (NH,)2[IrClj, retard the rate of de-
velopment of Ehrlich ascites carcinoma in
BALB/c mice and to a lesser degree the
development of the L1210 leukemia in BDF,
mice.
Metal Implants in Rats and Mice
Nothdurft (16-18) reported a high fre-
quency of appearance of tumors in rats and
mice at the sites of subcutaneously and intra-
peritoneally implanted discs, spheres, and
powderlike forms of the metals platinum,
gold, and silver and the nonmetal ivory. He
states, categorically, that the appearance of
tumors at the site of implantation is not
related to the chemical properties of the
metals, but unfortunately he does not adduce
results with positive and negative controls
to support the conclusion.
Human Chronic Exposure to Precious
Metals in Industry
Workers chronically exposed to precious
metal dusts and their complex salts in plati-
num metal refineries and in catalyst manu-
facture are subject to platinosis, a condition
whose signs are: cold symptoms, tightness in
the chest, dermatitis, eczema and skin ulcera-
tions. Fothergill (19) found none of the
symptoms of platinosis in workers exposed
to 5-70 4g/m3 of platinum dust only or to
complexes of precious metals other than plati-
num. Karasek and Karasek (20) identified
eight cases of allergic phenomena occurring
in the nasal mucosa, bronchi, and skin of
photographic studio personnel. They worked
with a sensitized paper containing potassium
chloroplatinite. Hunter et al. (21) described
the same syndrome in 52 of 91 men exposed
to dust or spray of complex salts of platinum
in four metal refineries in England. It started
with repeated sneezing, followed by profuse
running of the nose. Tightness of the chest
with shortness of breath, wheezing, cough,
and cyanosis ensued. Some 13 men also ex-
perienced a scaly erythematous dermatitis
and some an urticarial rash. These conditions
did not occur in workers exposed to much
higher concentrations of metallic platinum
in the atmosphere or to men exposed to the
complex salts of other precious metals in-
cluding palladium.
Two case histories reported were charac-
teristic: One person worked in the refinery
18 years and had symptoms after the first
year which became slowly but progressively
worse until he was forced to give up this
work. On leaving, the symptoms disappeared
and did not recur. The second person pre-
sented symptoms after six years of service,
becoming worse until asthma appeared in
the 10th year. After transfer to another
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from asthma.
Roberts (22) reviewed the previous re-
ports and cited the experience gained in a
five-year study of 21 employees of the
Bishop & Co. Platinum Works. He described
factors predisposing to platinosis: previous
history of allergy, strong family history of
hives, hay fever, asthma, contact dermatitis.
Individuals who have skin blemishes, moles,
acne, sebaceous cysts and other lesions are
prone to become sensitive to complex plati-
num salts. Those with blond hair, blue eyes,
and thin or transparent skin that tolerates
irritants poorly are prone to have platinosis.
More swarthy types, free from skin blemishes
with darker, coarse hair and thicker, less
sensitive skin do not usually develop the
platinum intolerance.
Biological Effects of Platinum Complexes
Since Rosenberg (14) reported the activity
of platinum complexes as antitumor agents
in test animals, considerable effort has been
made to study the effects in detail. The most
widely investigated of the compounds is
Peyrone's salt (23-26), cis-dichlorodiammi-
noplatinum(II) (cis-[Pt(NH,)2C1]). It has
displayed promising results in arresting
tumor growth in animals and has been intro-
duced into clinical trials for cancer treatment
in humans to establish appropriate dose
levels and schedules.
Preclinical Toxicology: Studies of toxi-
cology of cis-[Pt(NH)2C12] have been con-
ducted on mice and rats (27-30), and have
been summarized by Rosenberg (31). The
important histological changes observed in
these rodents were: denudation of intestinal
epithelium, bone marrow depression, thymic
and splenic atrophy, and acute nephrosis.
Trials with dogs and monkeys revealed
similar toxic effects with damage to the renal
tubules a prominent effect, especially at high
dose levels. Other important effects are dam-
age to the bone marrow and gastrointestinal
epithelium.
Clinical Experience: Phase I clinical
trials of cis-[Pt(NH3)2C12], administered
intravenously, were concluded in mid-1972.
In these trials with terminal cancer patients,
a number of toxic effects predicted from
animal studies were confirmed.
The clinical brochure (32) for cis-[Pt
(NH)2C12] includes the findings of clinicians
studying its behavior in humans. Therapeutic
efficacy was seen clinically in Phase I trials
in treatment of several types of tumors. Some
of the most encouraging results were re-
ported by Higby (33) on testicular tumors.
The major limitation on the use of this
complex as an antitumor agent is its renal
toxicity, usually manifested as tubular epi-
thelial damage. It has been estimated that
single IV doses above 2 mg/kg leads to un-
acceptable toxic effects. Other toxic effects
reported include ototoxicity, high-frequency
hearing loss, at total doses above 1 mg/kg.
Wallace (34) has reported no evidence of
cumulative renal toxicity in one patient who
received 545 mg/M2 (-..14 mg/kg) over a
104-day period (schedule unspecified). An-
other of his patients received a 479 mg
cumulative dose over a period of 200+ days;
the patient experienced a BUN elevation of
38 and a creatinine of 4.4 at the very ter-
minal stage of her disease with other com-
plicating factors.
Mechanism of Action: Extensive re-
search is under way to establish the mode
of antitumor action of this and related com-
plexes. Several interactions with the nucleic
acid constituents have been observed and are
under study. It has been suggested that
tumor destruction results from drug action
at sites in the cell resulting inprimary lesions
on the nuclear DNA (31). The principal
mechanism appears to involve inhibition of
DNA synthesis and, to a lesser degree, inhi-
bition of RNA and protein synthesis. Harder
and Rosenberg (35) reported selective in-
hibition of DNA synthesis in vitro by cis-
[Pt(NH3)2C12 below 5 XM.
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Biological Systems
Understanding the detailed interactions of
platinum group metals with biological sys-
tems requires extensive quantitation and
characterization of the chemical species in-
volved. Studies of chemical behavior of com-
plexes in relatively simple systems in vitro
suggest the large number of variables that
affect ligand substitution reactions and thus
the diversity of the reaction products.
Chemical Considerations
Quadrivalent platinum, Pt(IV), and palla-
dium, Pd(IV), form inert, inner orbital
(d2sp3) octahedral complexes.
The most stable square-planar complexes
are those of divalent platinum, Pt(II) with
dsp2 hybridization. Divalent palladium, Pd
(II), produces complexes of the same geome-
try; both are low-spin d8 systems.
Most of the cis-trans isomers of square-
planar complexes that have been isolated
are the relatively inert complexes of Pt(II).
In fact, the concept of a square configuration,
rather than a tetrahedral one was introduced
by Werner (36) because the tetrahedral
structure could not account for the two forms
of [Pt(NH3):.Cl] prepared more than a cen-
tury ago by Peyrone (23) and by Reiset (37).
Thermodynamic versus Kinetic Properties
of Complexes
The terms "stable" and "unstable" are used
to refer to the thermodynamic properties of
the complex species considered. The term
"inert" is used in the kinetic sense, to de-
scribe complexes which engage in ligand
replacement reactions slowly; those which
undergo such reactions rapidly are described
as "labile", as suggested by Taube (38).
While it is often true that stable substances
are slow to react and unstable compounds
react rapidly, there is no absolute require-
ment that this be the case. Synthesis of
various Pt(II) compounds rests on utilization
of competing thermodynamic and kinetic
factors. The behavior of the complexes with
biological materials will depend on the same
considerations; the distinction between ther-
modynamic and kinetic factors may be im-
portant in understanding the interactions.
Some metal complexes are so stable they do
not react with the biological system. Thus,
the stability (stability constant, K- 044) and
inertness (kinetics extremely slow) of the
complex [Fe(CN)G] 2- are so great, even in
acid solution, that it yields no significant
HCN; this cyanide complex could be ingested
with no ill effects.
Kinetics of the ligand substitution reaction
are important, since the half-times of the
reactions may range from less than a second
to months or years. The latter may appear
to be "stable" if only short studies are made.
The rates are functions of the geometry of
the complex, the metal and its oxidation state,
and the polarizability of the ligands. Photo-
chemical effects and pH may also affect re-
action rates.
Effect of Metal Oxidation State
Stability of oxidation states of metal com-
plexes in the biological medium must be
considered. Low-spin complexes generally
undergo rapid one-electron oxidation or re-
duction reactions. Since biological systems
operate at low redox potential, approximately
-0.5 to 0 V, reduced low oxidation states
usually obtain. Platinum group complexes
would be reduced to the metallic state under
these conditions but for their inert reduction
kinetics. Although Pt(IV) amines would be
expected to penetrate biological systems more
rapidly than Pt(II) amines, the latter pro-
duce the biological effect.
Photochemical Reactions
Photochemical processes may have an im-
portant role in the transformation of plati-
num complexes: Complexes of the type [Pt
(NH3)nCl4_]7-2 undergo photoaquation (39),
while cis-[Pt(NH3)2(HO)2] +2 photoisomer-
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and reductions have been reported (40,41).
Common Chemical Features of Antitumor
Complexes
Of the transition-metal complexes tested
for antitumor activity, only a small number
have shown it; some active compounds are
highly toxic. The effective compounds have
features in common that may aid us in un-
derstanding their interactions with biological
systems.
Some of these features are outlined here.
The complexes exchange some ligands ra-
pidly; other ligands are exchanged slowly or
not at all. This behavior is usually found in
low-spin complexes having electrons paired
in the t29 level d-oribitals. Strongly bound
ligands are transported with the metal
through membranes like cell walls. The geo-
metric configurations of transition metal
cations are: square-planar (usually low-spin,
d8), pentagonal square-pyramidal (usually
low-spin, d7), octahedral (all other low-spin
electronic configurations).
Active antitumor agents usually have two
exchangeable ligands in cis positions. The
ligand donor atoms most probable for the
low-oxidation state cations in a biological
system are N, 0, S, Cl, Br; these donor
atoms may be incorporated into a large
variety of ligands. Some ligands are mono-
dentate; others may be mono- or multi-
dentate. Chelation may occur with the latter.
Halide ligands can form bridges between
metals.
The activity of cis-[Pt(NH,),2Cl2] against
tumors is associated with reactions replacing
the halides. These complexes are bifunctional
reagents that may undergo nucleophilic sub-
stitution at two cis positions.
Antitumor behavior is apparently not re-
lated to oxidation-reduction reactions of the
metal.
Detailed Reaction Scheme
Square-planar complexes undergo predomi-
nantly bimolecular nucleophilic displacement
reactions in contrast to the generally disso-
ciative reactions exhibited by octahedral
complexes. Cis-[Pt(NH3)2C12], for example,
is injected as a neutral molecule in physio-
logic saline solution. This neutral species may
undergo limited hydrolysis in the extracellu-
lar fluid (,..O.lM Cl-). Within the cell, a
lower chloride ion concentration obtains
(0.004M Cl-) ; thus more extensive hydrolysis
may occur as indicated in the stepwise re-
action scheme (1), which assumes monomeric
species and preservation of the cis configura-
tion of the ammine ligands despite the
greater favorability of the trans configura-
tion thermodynamically. The stability con-
stants shown are cited by Balzini (41).
The rate constants for the successive aqua-
tion reactions (41) shown for cis-[Pt(NH3)2
C12] are kl,H2o = 2.5 X 10-5 sec-, k2,H2o=
3.3 X 10-5 sec-1; at 200C; thus these reactions
have half-times of the order of 6-8 hr (42).
Note that both ligand substitution rate and
partial equilibria for this type of reaction
may be functions of the pH and pC1 of the
surrounding medium. In a fluid low in Cl-
and, near neutral pH (e.g. cellular fluid), one
could expect to find approximately half of
the Pt as [Pt(NH3)2(H2O)OH]+1 and half
Cis- [Pt(NHa)2(OH)2]0
-H+1V+H+ pKa=7.3
cis- [Pt(NH3)2Cl(OH)] IH ci8- [Pt(NH3)2(H20) (OH)]+
-H+1 [+H+ -H+1 L+H+ pKa=5.6
Ci8- [Pt(NH3)2C121
H Cis- [Pt(NH3)2(H20) Cl]+ +H20 cis- [Pt(NH3)2(H20) 2]+2 (1)
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philes did not displace the hydroxo ligands
in the complex molecules.
Physiochemical Measurements:
Properties of Metal Complexes
Electronic absorption spectra yield infor-
mation on interactions between the metal
and bound groups, stability constants and
rate constants for complexation. Magnetic
and natural circular dichroism (CD) meas-
urements also yield useful information on
geometries and metal-ligand interactions.
Electron spin resonance (ESR) and nuclear
magnetic resonance (NMR) are useful in
determining symmetry relations, binding
constants and rate data. Vibrational spectra
may also be used for characterization of the
molecular structures.
A few studies reporting various biological
effects reflect known total quantities used in
the experiments, but few data are available
from analyses for the metal distributed in
the biological system. The available data
have come principally from tracer experi-
ments with radioactive platinum isotopes.
Renshaw and Thompson (43), performing
a tracer study %with 191Pt in B. cereus, S.
aureus, and E. coli, showed the bacteriocidal
[PtCl6] 2- is taken up by the cytoplasmic
protein. The photochemical reaction products
(principally [Pt(NH)2Cl04]) that produce
filamentous growth of the bacteria were
bound to nucleic acids and metabolic inter-
mediates, amino acids, peptides, and small
nucleic acids as well. Little 191Pt was bound
to the lipid material.
Unfortunately, the platinum radionuclides
present experimental difficulties because of
the short half-life of the radioactive isotopes
and relatively lengthy steps in synthesis and
purification of complexes. Studies of long
duration require low-level counting facilities
if tracer levels introduced initially are to be
kept at levels that do not require heroic safety
precautions.
Techniques for Quantitation
Quantitation of platinum can be performed
at relatively low concentrations by several
techniques including mass and emission spec-
trography, arc, spark, and M6ssbauer spec-
troscopy, x-ray fluorescence, neutron activa-
tion, and electronic and atomic absorption.
Standard Reference Materials
The biological Standard Reference Ma-
terials (SRM) available from the National
Bureau of Standards (NBS) (bovine liver
SRM 1577 and mixed orchard leaves SRM
1571) do not contain certified quantities of
Pt metals. Laboratories analyzing for these
metals have no biological standard to measure
their analytical techniques against.
The NBS does offer high purity platinum
wire, SRM 680, with a certified analysis
from which a hexachloroplatinic acid stand-
ard can be prepared. Our determinations by
use of atomic absorption spectrophotometry
have been based on standards prepared- from
highly purified Pt metal and a commercially
available hexachloroplatinic acid standard.
We plan independent analyses of the plati-
num in biological materials to confirm results
obtained by atomic absorption spectrometry.
One method to be used is neutron-activation
analysis usingthe reaction (2):
'n, I , -Y
198Pt.3% o99Pt . 99Au
0 =4b tl/2= 31m
7.3% abundance
(2)
199Au subsequently decays to 199Hg with a
3.15 day half-life.
Quantitation of Platinum in Biological
Samples
Analytical techniques have been evolved
to overcome difficulties specific to the types
of samples analyzed. Biological samples pre-
sent special considerations and difficulties;
they usually contain a substantial proportion
of water, and ionic metal species may bind so
strongly to amino acids and proteins that the
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analysis.
Experience with several procedures for
quantitation of platinum in biological samples
has led to development of a method that
yields reproducible results with tissue
samples of approximately 1 g wet weight
(or 1 ml samples of fluids like blood plasma
or urine) that contain 0.25 ,g Pt or more.
Measurements typically use a 20-ul portion
of digest taken up in lM HCI. Under favor-
able conditions, this method yields reliable
results with samples containing 2 ng Pt or
more.
If analytical results are to be reported on
the dry-weight basis, solid tissue is lyophil-
ized. Otherwise, the tissue is weighed wet.
The weighed tissue is wet-ashed in 10 ml
of a solution made from 1 volume HNO3
(60%0) + 1.5 volume HC104 (70%0). The
digestion step need not be carried out under
reflux. The temperature of the mixed acid
solution rises progressively as the HNO3 is
concentrated and volatilized with subsequent
concentration of the HCIO, and progressive
development of its full oxidation potential
(- 2 V) at 203°C, the boiling point of the
HCIO4-water azeotrope (acid strength
72.5%0). Experience has shown that some
tissues (e.g., liver, fat) may require repeated
treatment to yield a clear digest. Heating is
continued to incipient dryness of the digest,
whereupon 5 ml lM HCl are added and
evaporated again to incipient dryness. Fi-
nally, the contents of the beaker are taken
up into 5 ml iM HCI.
Portions of this solution (typically, 20 zd)
may be introduced directly into the heated
graphite analyzer (HGA-2000) coupled to a
Perkin-Elmer 303 atomic absorption spectro-
photometer to give consistent results at the
5 ng level or higher by using the 265.9 nm
resonance line for Pt.
An additional step using solvent extrac-
tion increases the sensitivity of the method.
The solvent, methyl isobutyl ketone (MIBK)
is used to extract the platinum species from
the aqueous phase. This solvent affords a
distribution coefficient virtually independent
of HCI concentration in the range 1-12M.
The atomic absorption measurement is then
made on a 20 pl portion of the solvent. Al-
though this step improves results, we have
experienced some unexplained variations in
yield with it and consider it premature to
recommend.
The solvent extraction technique and varia-
tions of it using the aliphatic secondary
amines LA-1 or LA-2 liquid ion-exchangers
in xylene as extractants are being developed
further. We have conducted some preliminary
separations using LA-1 since it offers higher
distribution coefficients than MIBK over the
1-9M HCI acidity range. Davidson and Jame-
son (44,45), showed that the extraction de-
pends not only on the HCl molarity in the
aqueous phase, but also on the concentration
of the background electrolyte anions in the
aqueous phase that compete for exchange
sites. Work is currently under wayto increase
the sensitivity of the analysis and improve
the reliability of the extraction step.
Summary
We have cited information on known inter-
actions of platinum-metal complexes with
bacteria, viruses and mammals. Effects in
humans have been noted for chronic indus-
trial exposure to platinum complex com-
pounds; clinical therapeutic experience with
cis-[Pt(NHW)2CX] has been reported. Knowl-
edge of biological and chemical behavior of
platinum metals is limited. Data available on
the quantities and chemical nature of the
materials issuing from converter equipped
test vehicles are insufficient to permit defini-
tive assessment of the risk posed by intro-
duction of these systems on a large scale.
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